Kundi Harun, Kiziltunc Emrullah, Korkmaz Ahmet, Cicek Gokhan, Ornek Ender, Ileri Mehmet
1 Cardiology Department, Ankara Numune Education and Research Hospital, Ankara, Turkey.
Clin Appl Thromb Hemost. 2018 Mar;24(2):273-278. doi: 10.1177/1076029617715118. Epub 2017 Jun 19.
The present study aimed to determine the long-term prognostic validity of the CHADS-VASc score in patients with acute myocardial infarction (AMI). In addition, we formulated a novel scoring system, the CHADS-VASc-CF (which includes cigarette smoking and a family history of coronary artery disease as risk factors). This study included 4373 consecutive patients with AMI who presented to the emergency department of our hospital and underwent cardiac catheterization procedures between December 2009 and September 2016. Among these patients, 1427 were diagnosed with ST elevation myocardial infarction (STEMI) and 2946 were diagnosed with non-STEMI. The study included 4373 patients. The study population was divided into 2 groups according to the occurrence of cardiovascular death during the follow-up period. Multivariate logistic regression analysis showed that the CHADS-VASc-CF score, CHADS-VASc score, major adverse cardiac events, current cigarette smoking, older age, hypertension, and family history of coronary artery disease were significantly higher, and that the left ventricular ejection fraction and glomerular filtration rate were significantly lower in the cardiovascular death (+) group. Using a cutoff score of >3 for the CHADS-VASc-CF score, long-term cardiovascular death was predicted with a sensitivity of 78.4% and specificity of 76.4%. The CHADS-VASc-CF score is suitable for use in all patients with AMI, regardless of the type of treatment, presence of atrial fibrillation, and type of AMI. This risk score, which is easy to calculate, provides important prognostic data. In the future, we think that interventional cardiologists will be able to use this novel scoring system to identify patients with a high risk of long-term cardiovascular death.
本研究旨在确定CHADS-VASc评分在急性心肌梗死(AMI)患者中的长期预后有效性。此外,我们制定了一种新的评分系统,即CHADS-VASc-CF(将吸烟和冠心病家族史作为危险因素)。本研究纳入了2009年12月至2016年9月期间连续入住我院急诊科并接受心脏导管检查的4373例AMI患者。其中,1427例被诊断为ST段抬高型心肌梗死(STEMI),2946例被诊断为非STEMI。研究共纳入4373例患者。根据随访期间心血管死亡的发生情况,将研究人群分为两组。多因素逻辑回归分析显示,CHADS-VASc-CF评分、CHADS-VASc评分、主要不良心脏事件、当前吸烟、老年、高血压和冠心病家族史在心血管死亡(+)组中显著更高,而左心室射血分数和肾小球滤过率显著更低。使用CHADS-VASc-CF评分>3作为临界值,预测长期心血管死亡的敏感性为78.4%,特异性为76.4%。CHADS-VASc-CF评分适用于所有AMI患者,无论治疗类型、房颤的存在与否以及AMI的类型。这种易于计算的风险评分提供了重要的预后数据。未来,我们认为介入心脏病学家将能够使用这种新的评分系统来识别长期心血管死亡风险高的患者。